Salarius Pharmaceuticals, Inc. — Director's Dealing 2016

Jan 25, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2016-01-21

Reporting Person: Wessel Thomas (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-21	Stock Option (right to buy)	$9.59	A	52000	Acquired	2026-01-21	Common Stock (52000.0)	Direct

Footnotes

F1: 25% of the total shares underlying this option vest on January 21, 2017 and the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.